255 related articles for article (PubMed ID: 17909269)
1. Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen.
Tozlu-Kara S; Roux V; Andrieu C; Vendrell J; Vacher S; Lazar V; Spyratos F; Tubiana-Hulin M; Cohen P; Dessen P; Lidereau R; Bièche I
J Mol Endocrinol; 2007 Oct; 39(4):305-18. PubMed ID: 17909269
[TBL] [Abstract][Full Text] [Related]
2. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
3. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
[TBL] [Abstract][Full Text] [Related]
4. The CGA gene as new predictor of the response to endocrine therapy in ER alpha-positive postmenopausal breast cancer patients.
Bièche I; Parfait B; Noguès C; Andrieu C; Vidaud D; Spyratos F; Lidereau R; Vidaud M
Oncogene; 2001 Oct; 20(47):6955-9. PubMed ID: 11687975
[TBL] [Abstract][Full Text] [Related]
5. High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors.
Marot D; Bieche I; Aumas C; Esselin S; Bouquet C; Vacher S; Lazennec G; Perricaudet M; Kuttenn F; Lidereau R; de Roux N
Endocr Relat Cancer; 2007 Sep; 14(3):691-702. PubMed ID: 17914099
[TBL] [Abstract][Full Text] [Related]
6. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
7. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.
Esslimani-Sahla M; Simony-Lafontaine J; Kramar A; Lavaill R; Mollevi C; Warner M; Gustafsson JA; Rochefort H
Clin Cancer Res; 2004 Sep; 10(17):5769-76. PubMed ID: 15355905
[TBL] [Abstract][Full Text] [Related]
9. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
11. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
[TBL] [Abstract][Full Text] [Related]
12. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
Hopp TA; Weiss HL; Parra IS; Cui Y; Osborne CK; Fuqua SA
Clin Cancer Res; 2004 Nov; 10(22):7490-9. PubMed ID: 15569979
[TBL] [Abstract][Full Text] [Related]
13. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
Gruvberger-Saal SK; Bendahl PO; Saal LH; Laakso M; Hegardt C; Edén P; Peterson C; Malmström P; Isola J; Borg A; Fernö M
Clin Cancer Res; 2007 Apr; 13(7):1987-94. PubMed ID: 17404078
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
[TBL] [Abstract][Full Text] [Related]
16. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.
Vendrell JA; Bieche I; Desmetz C; Badia E; Tozlu S; Nguyen C; Nicolas JC; Lidereau R; Cohen PA
Endocr Relat Cancer; 2005 Mar; 12(1):75-92. PubMed ID: 15788640
[TBL] [Abstract][Full Text] [Related]
17. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
Maier S; Nimmrich I; Koenig T; Eppenberger-Castori S; Bohlmann I; Paradiso A; Spyratos F; Thomssen C; Mueller V; Nährig J; Schittulli F; Kates R; Lesche R; Schwope I; Kluth A; Marx A; Martens JW; Foekens JA; Schmitt M; Harbeck N;
Eur J Cancer; 2007 Jul; 43(11):1679-86. PubMed ID: 17601725
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response.
Rydén L; Stendahl M; Jonsson H; Emdin S; Bengtsson NO; Landberg G
Breast Cancer Res Treat; 2005 Jan; 89(2):135-43. PubMed ID: 15692755
[TBL] [Abstract][Full Text] [Related]
19. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
20. Phospho-serine-118 estrogen receptor-alpha expression is associated with better disease outcome in women treated with tamoxifen.
Murphy LC; Niu Y; Snell L; Watson P
Clin Cancer Res; 2004 Sep; 10(17):5902-6. PubMed ID: 15355923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
